End-Stage Diastolic and Systolic Heart Failure: Evaluation and Timing of Heart Transplantation

摘要: End stage hypertrophic cardiomyopathy occurs in an estimated 3–15 % of patients and can present as either systolic or diastolic dysfunction. Risk factors for developing end disease include a family history disease, younger age at initial diagnosis, increased wall thickness persistent arrhythmia. The classic form adverse remodeling includes left ventricular cavity dilation with regression hypertrophy decrease ejection fraction. Standard medical therapy heart failure consideration prophylactic defibrillator is indicated when LVEF less than 50 %. Heart transplant viable option cardiomyopathy, including those failure, refractory Strategies used to bridge continuous inotropic infusion, assist device, intra-aortic balloon pump, rare cases extracorporeal membrane oxygenation. Survival after equal better survival who have other types cardiomyopathies.